Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Bone Biologics CorpBBLG · Entity 8560 | Director | September 28, 2026 | September 30, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Bone Biologics Corp
Report date September 28, 2026 · Filed September 30, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Non-Employee Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $0.50 · Expires 2036-09-28 | Direct | 113,896 |
Reported balance
After 2026-09-28 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-09-28 · Grant · Acquired 113,896 · Balance 113,896 F1: This option was granted under the Bone Biologics Corporation 2015 Equity Incentive Plan, in a transaction exempt under Rule 16b-3 and, except as otherwise provided in the award notice, vests infour equal quarterly installments. |
| Non-Employee Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $5.28 · Expires 2035-06-04 | Direct | 10,483 |
Reported balance
Holding disclosure · report date 2026-09-28 · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · Balance 10,483 F2: This option is fully exercisable as of the date of this report. |
| Non-Employee Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $10.38 · Expires 2034-09-17 | Direct | 5,119 |
Reported balance
Holding disclosure · report date 2026-09-28 · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · Balance 5,119 F2: This option is fully exercisable as of the date of this report. |
| Non-Employee Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $30.72 · Expires 2033-09-13 | Direct | 1,787 |
Reported balance
Holding disclosure · report date 2026-09-28 · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · Balance 1,787 F2: This option is fully exercisable as of the date of this report. |
| Non-Employee Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $2,323.58 · Expires 2027-08-23 | Direct | 26 |
Reported balance
Holding disclosure · report date 2026-09-28 · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · Balance 26 F2: This option is fully exercisable as of the date of this report. |
| Non-Employee Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $5,068.80 · Expires 2032-01-01 | Direct | 7 |
Reported balance
Holding disclosure · report date 2026-09-28 · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · Balance 7 F2: This option is fully exercisable as of the date of this report. |
| Non-Employee Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $7,560.00 · Expires 2031-10-26 | Direct | 3 |
Reported balance
Holding disclosure · report date 2026-09-28 · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · Balance 3 F2: This option is fully exercisable as of the date of this report. |
Filing footnotes · ownership attribution and instrument terms
F1: This option was granted under the Bone Biologics Corporation 2015 Equity Incentive Plan, in a transaction exempt under Rule 16b-3 and, except as otherwise provided in the award notice, vests infour equal quarterly installments.
F2: This option is fully exercisable as of the date of this report.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 28, 2026 Filed Sep 30, 2026 21:06 UTC | Bone Biologics Corp BBLG · Entity 8560 | GrantNon-Employee Stock Option · Derivative | 113,896 | $0.00 Strike: $0.50 | $0.00 |
DisclosureSEC source: 0001493152-26-045135 · ownership.xml · derivative · entry 1 Stroever Bruce · CIK 0001657728 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 113,896 Underlying: Common Stock · 113,896 shares Expires 2036-09-28 F1 · derivative.exercise_date: This option was granted under the Bone Biologics Corporation 2015 Equity Incentive Plan, in a transaction exempt under Rule 16b-3 and, except as otherwise provided in the award notice, vests infour equal quarterly installments. Read SEC document |
| June 04, 2025 Filed Jun 6, 2025 21:01 UTC | Bone Biologics Corp BBLG · Entity 8560 | GrantNon-Employee Stock Option · Derivative | 62,894 | $0.00 Strike: $0.88 | $0.00 |
DisclosureSEC source: 0001641172-25-014100 · ownership.xml · derivative · entry 1 Stroever Bruce · CIK 0001657728 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 62,894 Underlying: Common Stock · 62,894 shares Expires 2035-06-04 F1 · derivative.exercise_date: This option was granted under the Bone Biologics Corporation 2015 Equity Incentive Plan, in a transaction exempt under Rule 16b-3 and, except as otherwise provided in the award notice, vests in four equal quarterly installments. Read SEC document |
| September 17, 2024 Filed Sep 20, 2024 01:33 UTC | Bone Biologics Corp BBLG · Entity 8560 | GrantNon-Employee Stock Option · Derivative | 30,713 | $0.00 Strike: $1.73 | $0.00 |
DisclosureSEC source: 0001493152-24-037222 · ownership.xml · derivative · entry 1 Stroever Bruce · CIK 0001657728 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 30,713 Underlying: Common Stock · 30,713 shares Expires 2034-09-17 F1 · derivative.exercise_date: This option was granted under the Bone Biologics Corporation 2015 Equity Incentive Plan, in a transaction exempt under Rule 16b-3 and, except as otherwise provided in the award notice, vests and becomes exercisable quarterly through the date of the next annual meeting of stockholders of the Company. Read SEC document |
| September 18, 2023 Filed Sep 20, 2023 18:54 UTC | Bone Biologics Corp BBLG · Entity 8560 | GrantNon-Employee Stock Option · Derivative | 85,763 | $0.00 Strike: $0.64 | $0.00 |
DisclosureSEC source: 0001493152-23-033175 · ownership.xml · derivative · entry 1 Stroever Bruce · CIK 0001657728 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 85,763 Underlying: Common Stock · 85,763 shares Expires 2033-09-13 F1 · derivative.exercise_date: Vests quarterly through the date of the next annual meeting of the stockholders of the Company following the Grant. Read SEC document |
| August 23, 2022 Filed Mar 8, 2023 11:20 UTC | Bone Biologics Corp BBLG · Entity 8560 | GrantNon-Employee Stock Option · Derivative | 36,845 | $0.00 Strike: $1.61 | $0.00 |
DisclosureSEC source: 0001493152-23-006969 · ownership.xml · derivative · entry 1 Stroever Bruce · CIK 0001657728 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 48,516 Underlying: Common Stock · 36,845 shares Expires 2027-08-23 F1 · derivative.exercise_date: Quarterly through the date of the next annual meeting of the stockholders of the Company following the Grant. Read SEC document |
| January 01, 2022 Filed Feb 28, 2022 11:03 UTC | Bone Biologics Corp BBLG · Entity 8560 | GrantNon-Employee Stock Option · Derivative | 8,722 | $0.00 Strike: $3.52 | $0.00 |
DisclosureSEC source: 0001493152-22-005545 · ownership.xml · derivative · entry 2 Stroever Bruce · CIK 0001657728 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,671 Underlying: Common Stock · 8,722 shares Expires 2032-01-01 F1 · derivative.exercise_date: Quarterly through the date of the next annual meeting of the stockholders of the Company following the Grant. Read SEC document |
| October 26, 2021 Filed Feb 28, 2022 11:03 UTC | Bone Biologics Corp BBLG · Entity 8560 | GrantNon-Employee Stock Option · Derivative | 2,949 | $0.00 Strike: $5.25 | $0.00 |
DisclosureSEC source: 0001493152-22-005545 · ownership.xml · derivative · entry 1 Stroever Bruce · CIK 0001657728 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,949 Underlying: Common Stock · 2,949 shares Expires 2031-10-26 Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.